1 The 2019 Flemish consensus on screening for overt diabetes in early

2 pregnancy and screening for gestational diabetes mellitus

3 Katrien Benhalima¹, Caro Minschart¹, Paul Van Crombrugge², Peggy Calewaert¹, Johan Verhaeghe³,
4 Siska Vandamme³, Katrien Theetaert³, Roland Devlieger³, Leen Pierssens⁴, Hannah
5 Ryckeghem², Els Dufraimont⁵, Chris Vercammen⁶, Ann Debie⁶, Christophe De Block⁷, Griet
6 Vandenberghe⁸, Sylva Van Imschoot⁹, Sabine Verstraete¹⁰, Luk Buyse¹⁰, Johan Wens¹¹, Joke
7 Muyldermans¹¹, Anissa Meskal¹³, Sandy De Spiegeleer¹⁴, Chantal Mathieu¹

8 ¹Department of Endocrinology, University hospital Gasthuisberg, KU Leuven, Herestraat 49,
9 3000 Leuven, Belgium; katrien.benhalima@uzleuven.be; caro.minschart@kuleuven.be;
10 peggy.calewaert@uzleuven.be; chantal.mathieu@uzleuven.be

11 ²Department of Endocrinology, OLV ziekenhuis Aalst-Asse-Ninove, Moorselbaan 164, 9300
12 Aalst,Belgium;Paul.Van.Crombrugge@olvz-aalst.be;hannah.ryckeghem@olvz-aalst.be;

13 ³Department of Obstetrics & Gynecology, University hospital Gasthuisberg, KU Leuven,
14 Herestraat 49, 3000 Leuven, Belgium;johan.verhaeghe@uzleuven.be;
15 siska.vandamme@uzleuven.be;katrien.theetaert@uzleuven.be,
16 roland.devlieger@uzleuven.be

17 ⁴Department of clinical Biology, OLV ziekenhuis Aalst-Asse-Ninove, Moorselbaan 164, 9300
18 Aalst,Belgium; leen.pierssens@olvz-aalst.be

19 ⁵Department of Obstetrics & Gynecology, Imelda ziekenhuis, Imeldalaan 9, 2820 Bonheiden,
20 Belgium; Els.Dufraimont@imelda.be

21 ⁶Department of Endocrinology Imelda ziekenhuis, Imeldalaan 9, 2820 Bonheiden, Belgium;
22 Chris.Vercammen@imelda.be; ann.debie@imelda.be

23 ⁷Department of Endocrinology-Diabetology-Metabolism, Antwerp University Hospital,
24 Wilrijkstraat 10, 2560 Edegem, Belgium; Christophe.DeBlock@uza.be

25 ⁸Department of Obstetrics & Gynecology, Ghent University Hospital, Corneel Heymanslaan
26 10, 9000 Ghent, Belgium, Griet.Vandenberghe@uzgent.be

27 ⁹Department of Endocrinology, AZ St Jan Brugge, Ruddershove 10, 8000 Brugge, Belgium;
28 sylva.vanimschoot@azsintjan.be

29 ¹⁰Diabetes Liga, Ghent, Belgium; Sabine.Verstraete@diabetes.be; Luk.Buyse@vub.be

30 ¹¹Department of Primary and Interdisciplinary Care, University of Antwerp, Wilrijk, Belgium;
31 johan.wens@uantwerpen.be

32 ¹²midwife in private practice, Haantjeslei 185-01 - 2018 Antwerpen;
33 joke_muyldermans@hotmail.com

34 ¹³Anissa Meskal, department of Clinical Biology, GZA, Oosterveldlaan 24, 2610 Wilrijk,
35 Anissa.Meskal@gza.be

¹⁴Sandy De Spiegeleer, department of Clinical Biology, Laboratoire Luc Olivier SA, Rue
Léopold Genicot 16, 5380 Fernelmont; s.de.spiegeleer@labolivier.eu

Abstract

Screening for gestational diabetes mellitus (GDM) is important to improve pregnancy outcomes and to prevent type 2 diabetes after pregnancy. The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75g oral glucose tolerance test (OGTT) for screening of GDM. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence and increased workload. After review of the latest evidence and based on data from the 'Belgian Diabetes in Pregnancy' study, members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (VVOG), midwives (VVOB), diabetes nurse educators (BVVDV) and clinical chemists (RBSLM) have reached a new consensus on screening for GDM in Flanders. This new consensus recommends universal screening for overt diabetes when planning pregnancy or at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose by using the same diagnostic criteria as in the non-pregnant state. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a previous history of GDM, lifestyle counselling is advised with screening for GDM with a 75g OGTT at 24 weeks. In all other women, we recommend a two-step screening strategy with a 50g glucose challenge test (GCT) at 24 weeks followed by a 75g OGTT when the glucose level 1 hour after the GCT $\geq 130\text{mg/dl}$. Diagnosis of GDM is made using the IADPSG criteria for GDM. Postpartum screening for subsequent glucose abnormalities should be advocated and organized for every woman with GDM.

Key words: gestational diabetes mellitus, screening, pregnancy, consensus, type 2 diabetes

Introduction

Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or third trimester of pregnancy provided that overt diabetes early in pregnancy has been excluded [1]. Screening and treatment of GDM between 24-28 weeks of pregnancy reduces the risk for pregnancy complications such as large-for-gestational age infants (LGA) and preeclampsia [2 3]. Women with a history of GDM and their offspring, are at increased risk to develop type 2 diabetes (T2DM) later in life [4 5].

The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75g oral glucose tolerance test (OGTT) for screening of GDM with the use of more stringent diagnostic criteria [6]. Since the adoption of the IADPSG recommendation by the World Health Organization (WHO), the IADPSG criteria are commonly referred to as the 2013 WHO criteria [7]. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence, increased workload, the need for a fasting test and the risk for increased medicalization of care [8-10]. As a consequence, there still is a large variation in screening strategies for GDM used across Europe. A survey in 2015 demonstrated that the majority of European societies still recommended screening based on risk factors, about one third recommended a universal one-step approach with a 75g OGTT [11].

After weighing of the advantages and disadvantages, the 2012 Flemish consensus on screening for GDM recommended not to implement the IADPSG screening strategy for GDM but to continue with a universal two-step screening strategy with the 50g glucose challenge test (GCT) and 3-hour 100g OGTT with the Carpenter & Coustan criteria for GDM [12]. To obtain data on the impact of the IADPSG screening strategy in Belgium and to evaluate the

diagnostic accuracy of different screening strategies for GDM, the ‘Belgian Diabetes in Pregnancy-North’ study (BEDIP-N) was performed from 2014-2018. After review of the evidence including data from the completed BEDIP-N study, the 2012 Flemish consensus on screening for GDM was now revised. A discussion meeting was held on 22-01-2019 between members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (Vlaamse Vereniging voor Obstetrie en Gynaecologie ‘VVOG’), midwives (Vlaamse Beroepsvereniging voor Vroedvrouwen ‘VBOV’), diabetes nurse educators (Beroepsvereniging Vlaamse diabetesverpleegkundigen ‘BVVDV’) and clinical chemists (Royal Belgian Society Laboratory Medicine ‘RBSLM’) which led to current consensus statement on screening for GDM in Flanders. Before the consensus meeting, data on the BEDIP-N study were made available to all attendees and the consensus paper was further revised based on the comments given after the consensus meeting.

Counselling when planning pregnancy

Several studies have shown that both maternal GDM and obesity are independently associated with adverse pregnancy outcomes [13 14]. Since the placenta may already be programmed in early pregnancy, achieving optimal metabolic health before a planned pregnancy, might be the best strategy to obtain good pregnancy outcomes. Although several randomized controlled trials (RCT’s) investigating lifestyle interventions in overweight or obese women during pregnancy, demonstrated a significant reduction in gestational weight gain, this was generally not associated with a reduction in the rate of GDM or other pregnancy complications [15-18]. The consensus recommends therefore that overweight and obese women should lose weight before pregnancy to improve pregnancy outcomes. In addition, since excessive weight gain during pregnancy is also an independent risk factor for

adverse pregnancy outcomes in normal weight women, lifestyle counselling should be considered for all woman before pregnancy [19]. Lifestyle counselling can be given by a general physician, dietician or midwife. Lifestyle advice should be in line with the general Belgian recommendations for a healthy lifestyle (if overweight weight loss $\geq 5\%$ of body weight, ≥ 30 minutes of moderate exercise per day and food recommendations according to the food triangle (www.gezondleven.be/themas/voeding/voedingsdriehoek)).

Screening for overt diabetes in early pregnancy

Due to the increasing prevalence of T2DM in women of childbearing age, many international associations recommend to screen for overt diabetes when planning pregnancy or at first prenatal contact [16]. Women with diabetes are at an increased risk for congenital anomalies and diabetes complications due to their greater degree of hyperglycaemia earlier in pregnancy [1]. These women need rapid treatment with insulin and close follow-up during and after pregnancy. The current consensus endorses therefore the recommendation of 2012 to universally screen for overt diabetes at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose (FPG) by using the same diagnostic criteria as in the non-pregnant state [12] (Figure 1). In addition, a novel (pre-clinical) autoimmune type 1 diabetes should be excluded when alarm signs are present such as weight loss, symptoms related to the rapid development of hyperglycaemia (polyuria, thirst...), important glucosuria, the presence of polyhydramnios and fetal macrosomia.

The OGTT is considered to be the golden standard for diagnosis of diabetes but is not practical as a screening test, as it is difficult to implement in out-patient clinics, has a low reproducibility and a high cost. The consensus recommends therefore to screen with a FPG since this has the advantage that it is relatively easy to perform at a low cost. In addition,

FPG has shown to diagnose more people with T2DM than HbA1c [20]. Moreover, the HbA1c test is not reimbursed for screening in Belgium. However, when it is not possible to come fasting for the test, HbA1c can be used as an alternative to diagnose T2DM (HbA1c $\geq 6.5\%$). The measurement of glycosuria is not recommended as this has a very low sensitivity to detect diabetes and is frequently false positive in pregnancy [21].

To limit excessive gestational weight gain, lifestyle counselling is also recommended in early pregnancy, especially in overweight and obese women. The 2009 Institute of Medicine (IOM) targets for gestational weight gain are recommended [22] (Table 1). More recent research has shown that obese women who can limit gestational weight gain ≤ 5 kg have a lower LGA rate [23 24]. Lower weight gain targets for obese women than the 2009 IOM guidelines might therefore be considered.

Impaired fasting glycaemia in early pregnancy

There is currently not enough evidence to recommend screening and treatment of GDM before 24-28 weeks of gestation. The IADPSG Consensus Panel initially recommended that a fasting glucose ≥ 92 mg/dl in early pregnancy should be classified as GDM [6]. This recommendation is much debated as this was reached by consensus only and is merely based on data extrapolated from the cut-off value used on the 75g OGTT later in pregnancy. In 2016, the IADPSG stated that it cannot longer recommend screening for GDM in early pregnancy due to lack of data from intervention studies on GDM in early pregnancy and the fact that the fasting glucose generally further decreases by the end of the first trimester and is therefore a poor predictor for GDM later in pregnancy [25]. There are currently no data from RCT's demonstrating benefit of early screening and treatment of GDM to improve pregnancy outcomes but several studies are ongoing (NCT1926457, NCT01864564 and

170 NCT02708758). In the BEDIP-N study women with impaired fasting glycaemia in early
171 pregnancy were often obese and/or had a metabolic syndrome (unpublished data). Due to
172 the lack of evidence, we propose a pragmatic approach using the definition of impaired
173 fasting glycaemia (100-125mg/dl) in early pregnancy according to American Diabetes
174 Association (ADA) criteria for prediabetes as in the non-pregnant state. The consensus
175 recommends that women with impaired fasting glycaemia in early pregnancy, should receive
176 lifestyle counselling, with screening for GDM with a 75g OGTT at 24 weeks using the IADPSG
177 criteria (Figure 1). There is currently no evidence that women with impaired fasting
178 glycaemia in early pregnancy would benefit from self-monitoring of blood glucose (SMBG).
179 In addition, since this is also not reimbursed and to avoid increased medicalization of care,
180 the consensus does not recommend SMBG in these women.

181 Not all gestational hyperglycaemia has the same etiology. Autoimmune type 1 diabetes and
182 undetected monogenetic forms of diabetes such as the maturity-onset diabetes of the
183 young MODY-2, can be first revealed during pregnancy masquerading as impaired fasting
184 glycaemia or GDM. People with MODY-2 have a an inactivating mutation of the glucokinase
185 gene, leading to a defect in glucose sensing and their glucose homeostasis is therefore
186 maintained at a higher set point, resulting in a mild asymptomatic fasting hyperglycaemia
187 [26]. Since glucose-lowering therapy is ineffective in people with MODY-2 and because the
188 lack of long-term complications, treatment is not recommended outside pregnancy. When
189 both mother and child have the genetic mutation predisposing to MODY-2, the fetus has
190 poor insulin secretion and treating maternal hyperglycaemia may result in inadequate
191 intrauterine growth. In pregnancy, insulin treatment of the mother is therefore only
192 appropriate when increased fetal growth on scanning suggests the fetus is unaffected [27].

Screening for GDM at 24 weeks of pregnancy

The 'Hyperglycemia and Adverse Pregnancy Outcomes' (HAPO) study showed a continuous and graded relationship between maternal hyperglycaemia and the risk for an adverse perinatal outcome [28]. Based on the HAPO study, the IADPSG recommended a universal one-step approach with the 75g OGTT for screening of GDM with the use of more stringent diagnostic criteria for GDM [6]. However, the IADPSG recommendation for screening for GDM remains controversial due to the important increase in the number of women labeled and treated as GDM. The BEDIP-N study has shown that the prevalence of GDM would double to 12.5 % in Belgium using the one-step approach with 75g OGTT and IADPSG criteria compared to a two-step screening strategy with a 50g GCT with a subsequent 75g OGTT only when the GCT is abnormal [29 30]. In addition, since the one-step diagnostic approach with the 75g OGTT will lead to an important increase in workload, alternative screening strategies need to be investigated that can limit the number of OGTT's [8]. The GCT has the advantage that it can be performed in the non-fasting state and can easily be organized in primary care. By using a two-step screening strategy with a GCT, the OGTT could be avoided in many women but data were lacking on the sensitivity and specificity of the GCT with the IADPSG criteria.

The BEDIP-N study was a large Belgian multi-centric prospective cohort study enrolling 2006 pregnant women in early pregnancy to evaluate the diagnostic accuracy of different screening strategies for GDM based on the IADPSG criteria. During the study, both health care providers and participants were blinded for the GCT. All participants received therefore a 75g OGTT irrespective of the result of the GCT. The BEDIP-N study has recently shown that the GCT has a moderate diagnostic accuracy in a universal two-step screening strategy for

216 GDM using the IADPSG criteria and that the threshold of the GCT would need to be reduced
217 to at least 130mg/dl to achieve a sensitivity $\geq 72\%$ [29]. By using a GCT $\geq 130\text{mg/dl}$ as cut-off,
218 65% of all OGTT's could be avoided [29]. In addition, the BEDIP-N study has demonstrated
219 that a modified two-step screening strategy combining the GCT $\geq 130\text{mg/dl}$ with clinical risk
220 factors may be a practical alternative to the universal one-step approach with the 75g OGTT
221 [31]. In this modified two-step screening strategy, women with a BMI $\geq 30 \text{ Kg/m}^2$ and/or a
222 previous history of GDM would immediately receive an OGTT at 24 weeks since they are at
223 high risk for GDM while women without any of these risk factors would be screened with a
224 GCT [31]. This strategy can reduce the workload and the need for an OGTT in nearly 60% of
225 women while reducing the number of women that would be missed with GDM (Figure 2).
226 Moreover, the BEDIP-N study showed that the GCT was generally better tolerated than an
227 OGTT and more women preferred a GCT [31].

228 In contrast to the 2012 consensus, the current consensus recommends a 75g OGTT with the
229 IADPSG criteria for the diagnosis of GDM since these criteria are the first diagnostic criteria
230 based on pregnancy outcomes. However, data on the cost-effectiveness of a universal one-
231 step approach with 75g OGTT and IADPSG are conflicting and the one-step screening
232 strategy labels milder forms of hyperglycaemia as GDM with an increased risk for
233 medicalization of care during pregnancy and possibly a lower long-term risk for glucose
234 intolerance postpartum [8 19]. The consensus recommends therefore a universal two-step
235 screening strategy with a GCT in women without obesity and without a history of GDM [8
236 32]. Since the BEDIP-N study has demonstrated that the threshold of the GCT should be
237 reduced to 130mg/dl when used with the IADPSG criteria, the current recommendation is to
238 use a universal two-step screening strategy with a 50g GCT at 24 weeks followed by a 75g
239 OGTT when GCT $\geq 130\text{mg/dl}$ with the use of the IADPSG criteria for GDM (Figure 1). In line

with the BEDIP-N results on a modified two-step screening strategy, for obese women and women with a history of GDM, a universal one-step approach with a 75g OGTT at 24 weeks is now recommended (Figures 1-2). In addition, the recommendation is to screen for GDM rather earlier around 24 weeks and certainly before 28 weeks to allow for timely treatment of GDM.

Screening for GDM in women after bariatric surgery

Since bariatric surgery is currently the most successful way to achieve maintained weight loss, increasing numbers of obese women of childbearing age receive bariatric surgery. Bariatric surgery performed before pregnancy significantly reduces the risk to develop GDM but the risk in these women is generally still higher compared to normal weight pregnant women [33]. Women after bariatric surgery therefore still require screening for GDM, which is challenging. The standard screening tests (GCT and OGTT) are often not well tolerated and wide variations in glucose excursions make the diagnosis difficult [33]. The poor tolerance of the OGTT in patients with bariatric surgery is due to the high risk for early dumping and postprandial hyperinsulinemic hypoglycaemia after ingestion of the glucose load. A large retrospective cohort study showed that pregnant women after a gastric bypass had more often a high glucose excursion at 1 hour and 55% had a reactive hypoglycaemia at 2 hours [34]. Since there are currently no good tests available to screen for GDM, the consensus suggests a pragmatic approach to evaluate dysglycaemia in pregnant women with bariatric surgery [33]. Women with bariatric surgery should first receive screening for overt diabetes at first prenatal visit by measuring the fasting glycaemia. To evaluate dysglycaemia later in pregnancy, the recommendation is to record capillary blood glucose daily before and 1 or 2 hours after each meal during 3-7 days at 24-28 weeks of pregnancy. For the diagnostic

glycaemic targets, we propose to use the same targets recommended by the ADA for the treatment of GDM (fasting glycaemia < 95mg/dl, 1-hour after the meal < 140mg/dl or 2-hours after the meal < 120mg/dl) [33].

Treatment of GDM

Initial treatment of GDM involves diet modification, glucose monitoring (fasting and 1-hour or 2-hours after each meal) and moderate exercise. Evidence-based data concerning nutritional treatment for GDM are limited. In general the recommendation is to reduce the caloric intake of obese women by approximately one-third while maintaining a minimum intake of 1600-1800 kcal per day, to limit the carbohydrate intake to 35-45% of total calories without compensatory increased intake of saturated fat, to avoid the intake of carbohydrates with a high glycaemic index and to perform daily moderate exercise for 30 minutes or more [19]. The generally recommended glycaemic targets for the treatment of GDM are fasting glycaemia < 95mg/dl, 1-hour after the meal <140mg/dl or 2-hours after the meal < 120mg/dl [1].

If lifestyle is insufficient to maintain the glycaemic targets after 1-2 weeks, pharmacological therapy with insulin becomes necessary. Recent studies have suggested that metformin and glibenclamide (glyburide) may be safe and acceptable alternatives for insulin for the treatment of GDM [19]. However, the need for supplemental insulin in women on metformin is around 30% and increased risks for neonatal hypoglycaemia and macrosomia have been reported in women treated with glibenclamide [35]. Moreover, there is a paucity of long-term follow-up data on children exposed to oral agents in utero and recent data suggest that exposure to metformin in utero might be associated with increased offspring weight [36 37]. Insulin remains therefore the first choice when lifestyle measures are

286 insufficient to achieve good glycemic control. The long acting insulins, human neutral
287 protamine Hagedorn (NPH) and insulin analogue detemir as well as the short acting insulins,
288 human regular and insulin analogues lispro and aspart (including the faster acting aspart),
289 are all approved for use during pregnancy [1]. Detemir is however only reimbursed for the
290 treatment of type 1 diabetes in Belgium. The long-acting insulin analogue glargine is not
291 approved for use in pregnancy but there are a large number of observational data showing
292 no adverse effects when used in pregnancy [12]. The recommendation of the 'Belgium
293 Federal Agency of Medicinal Agents' is that when considered necessary, the use of glargine
294 in pregnancy can be considered [12]. There are no data yet on the safety of the long-acting
295 insulin analogues glargine U300 and degludec in pregnancy.

296 **Follow-up postpartum**

297 By diagnosing GDM, a group of women at high risk to develop T2DM and cardiovascular
298 disease later in life is identified [4]. Lifestyle interventions and metformin can prevent
299 progression to T2DM on the long-term [38]. A healthy lifestyle postpartum should therefore
300 be stimulated in all women with a history of GDM. However, outside clinical studies
301 attendance rates at screening tests postpartum are often low, with only 30-50% of women
302 with recent GDM receiving an OGTT and follow-up rates after one year dropping further
303 [39]. This is a missed opportunity to timely identify and treat high-risk women for glucose
304 intolerance. The 'Zoet Zwanger' project is a Flemish GDM recall register coordinated by the
305 Diabetes Liga with the aim to increase the awareness on the long-term risk for diabetes.
306 Women registered in 'Zoet Zwanger', receive annual reminders to get a yearly screening test
307 in primary care [39].

308 Data on the risk to develop T2DM in women with GDM diagnosed by the one-step approach
309 and IADPSG criteria are limited. Before the introduction of the IADPSG screening strategy,
310 studies have shown that 30-50% of women with GDM develop T2DM within the first 10
311 years after the index pregnancy [4]. The use of the IADPSG criteria for GDM results in a
312 greater proportion of women diagnosed with mild forms of GDM, which might lead to a
313 lower proportion at risk for postpartum glucose intolerance. In the BEDIP-N study nearly
314 20% of women with GDM based on a universal one-step approach with the IADPSG criteria
315 had glucose intolerance in early postpartum [40]. In contrast, research from UZ Leuven has
316 shown glucose intolerance in 42% three months postpartum in women with GDM diagnosed
317 by a two-step screening strategy with the IADPSG criteria [30]. The majority of women with
318 glucose intolerance had an abnormal 2-hour glucose level on the OGTT (Impaired glucose
319 tolerance). IGT is an important risk factor for T2DM, since the highest cumulative incidence
320 to develop T2DM is seen in people with combined impaired fasting glycaemia/IGT, followed
321 by isolated IGT with the lowest incidence in patients with impaired fasting glycaemia [41].
322 Moreover, the BEDIP-N study shows that combining FPG and HbA1c in early postpartum,
323 does not improve the accuracy to detect glucose intolerance [40]. The consensus
324 recommends therefore a 75g OGTT 6-12 weeks postpartum in all women with a history of
325 GDM (Figure 1). In addition, all women should be offered registration in 'Zoet Zwanger'. On
326 the long-term, OGTTs result in lower costs per case detected than FPG or HbA1c [42]. When
327 glucose intolerance is found, the frequency of screening should be increased to at least
328 annually [43].

329 Breastfeeding (at least 3-6 months) should be stimulated, since this is associated with a
330 reduced risk to develop T2DM [44]. The postpartum OGTT should ideally be planned when
331 breastfeeding is stopped and should at the latest be planned 6 months postpartum.

Conclusion

The 2019 Flemish consensus on GDM recommends universal screening for overt diabetes when planning pregnancy or at first prenatal contact, preferably by measuring FPG. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a history of GDM, lifestyle counselling is advised with screening for GDM with a 75g OGTT at 24 weeks. In all other women, the consensus recommends the use of a universal two-step screening strategy with a 50g GCT at 24 weeks followed by a 75g OGTT when GCT ≥ 130 mg/dl with the use of the IADPSG criteria for GDM.

References

1. American Diabetes A. Standards of medical care in diabetes--2013. *Diabetes care* 2013;36 Suppl 1:S11-66 doi: 10.2337/dc13-S011[published Online First: Epub Date]].
2. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *The New England journal of medicine* 2005;352(24):2477-86 doi: 10.1056/NEJMoa042973[published Online First: Epub Date]].
3. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *The New England journal of medicine* 2009;361(14):1339-48 doi: 10.1056/NEJMoa0902430[published Online First: Epub Date]].
4. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* 2009;373(9677):1773-9 doi: 10.1016/S0140-6736(09)60731-5[published Online First: Epub Date]].
5. Grunnet LG, Hansen S, Hjort L, et al. Adiposity, Dysmetabolic Traits, and Earlier Onset of Female Puberty in Adolescent Offspring of Women With Gestational Diabetes Mellitus: A Clinical Study Within the Danish National Birth Cohort. *Diabetes care* 2017;40(12):1746-55 doi: 10.2337/dc17-0514[published Online First: Epub Date]].
6. International Association of D, Pregnancy Study Groups Consensus P, Metzger BE, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes care* 2010;33(3):676-82 doi: 10.2337/dc09-1848[published Online First: Epub Date]].
7. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. *Diabetes research and clinical practice* 2014;103(3):341-63
8. Benhalima K, Mathieu C, Damm P, et al. A proposal for the use of uniform diagnostic criteria for gestational diabetes in Europe: an opinion paper by the European Board & College of Obstetrics and Gynaecology (EBCOG). *Diabetologia* 2015;58(7):1422-9 doi: 10.1007/s00125-015-3615-7[published Online First: Epub Date]].
9. Ryan EA. Diagnosing gestational diabetes. *Diabetologia* 2011;54(3):480-6 doi: 10.1007/s00125-010-2005-4[published Online First: Epub Date]].
10. Cundy T, Ackermann E, Ryan EA. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. *Bmj* 2014;348:g1567 doi: 10.1136/bmj.g1567[published Online First: Epub Date]].
11. Benhalima K, Mathieu C, Van Assche A, et al. Survey by the European Board and College of Obstetrics and Gynaecology on screening for gestational diabetes in Europe. *European journal of obstetrics, gynecology, and reproductive biology* 2016;201:197-202 doi: 10.1016/j.ejogrb.2016.04.003[published Online First: Epub Date]].
12. K Benhalima for the consensus group. The VDV-VVOG-Domus Medica consensus 2012 on screening for pregestational diabetes in pregnancy and screening for gestational diabetes. *P Belg Roy Acad Med* 2013;2:24-42
13. Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. *Diabetes care* 2012;35(4):780-6 doi: 10.2337/dc11-1790[published Online First: Epub Date]].
14. Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. *Diabetes care* 2013;36(1):56-62 doi: 10.2337/dc12-0741[published Online First: Epub Date]].
15. Poston L, Bell R, Croker H, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *The lancet. Diabetes & endocrinology* 2015;3(10):767-77 doi: 10.1016/S2213-8587(15)00227-2[published Online First: Epub Date]].

16. Simmons D, Devlieger R, van Assche A, et al. Effect of Physical Activity and/or Healthy Eating on GDM Risk: The DALI Lifestyle Study. *The Journal of clinical endocrinology and metabolism* 2017;102(3):903-13 doi: 10.1210/jc.2016-3455[published Online First: Epub Date] |.
17. Koivusalo SB, Rono K, Klemetti MM, et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. *Diabetes care* 2016;39(1):24-30 doi: 10.2337/dc15-0511[published Online First: Epub Date] |.
18. Dodd JM, Turnbull D, McPhee AJ, et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. *Bmj* 2014;348:g1285 doi: 10.1136/bmj.g1285[published Online First: Epub Date] |.
19. Benhalima K, Devlieger R, Van Assche A. Screening and management of gestational diabetes. Best practice & research. *Clinical obstetrics & gynaecology* 2015;29(3):339-49 doi: 10.1016/j.bpobgyn.2014.07.026[published Online First: Epub Date] |.
20. International Expert C. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes care* 2009;32(7):1327-34 doi: 10.2337/dc09-9033[published Online First: Epub Date] |.
21. Buhling KJ, Elze L, Henrich W, et al. The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes. *European journal of obstetrics, gynecology, and reproductive biology* 2004;113(2):145-8 doi: 10.1016/j.ejogrb.2003.06.013[published Online First: Epub Date] |.
22. Weight Gain During Pregnancy: Reexamining the Guidelines. In: Rasmussen KM YA, ed.: In National Academies Press (US). *The National Academies Collection: Reports funded by National Institutes of Health*, 2009.
23. Asbjornsdottir B, Rasmussen SS, Kelstrup L, Damm P, Mathiesen ER. Impact of restricted maternal weight gain on fetal growth and perinatal morbidity in obese women with type 2 diabetes. *Diabetes care* 2013;36(5):1102-6 doi: 10.2337/dc12-1232[published Online First: Epub Date] |.
24. Bogaerts A, Ameye L, Martens E, Devlieger R. Weight loss in obese pregnant women and risk for adverse perinatal outcomes. *Obstetrics and gynecology* 2015;125(3):566-75 doi: 10.1097/AOG.0000000000000677[published Online First: Epub Date] |.
25. McIntyre HD, Sacks DA, Barbour LA, et al. Issues With the Diagnosis and Classification of Hyperglycemia in Early Pregnancy. *Diabetes care* 2016;39(1):53-4 doi: 10.2337/dc15-1887[published Online First: Epub Date] |.
26. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. *Diabetes care* 2015;38(7):1383-92 doi: 10.2337/dc14-2769[published Online First: Epub Date] |.
27. Iafusco D, Galderisi A, Lombardo F, et al. All classifications not built on pathogenesis become inadequate sooner or later. *Diabetologia* 2011;54(6):1583-4 doi: 10.1007/s00125-011-2113-9[published Online First: Epub Date] |.
28. Group HSCR, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. *The New England journal of medicine* 2008;358(19):1991-2002 doi: 10.1056/NEJMoa0707943[published Online First: Epub Date] |.
29. Benhalima K, Van Crombrugge P, Moyson C, et al. The Sensitivity and Specificity of the Glucose Challenge Test in a Universal Two-Step Screening Strategy for Gestational Diabetes Mellitus Using the 2013 World Health Organization Criteria. *Diabetes care* 2018 doi: 10.2337/dc18-0556[published Online First: Epub Date] |.
30. Benhalima K, Jegers K, Devlieger R, Verhaeghe J, Mathieu C. Glucose Intolerance after a Recent History of Gestational Diabetes Based on the 2013 WHO Criteria. *PloS one* 2016;11(6):e0157272 doi: 10.1371/journal.pone.0157272[published Online First: Epub Date] |.
31. Benhalima K, Van Crombrugge P, Moyson C, et al. A Modified Two-Step Screening Strategy for Gestational Diabetes Mellitus Based on the 2013 WHO Criteria by Combining the Glucose

- Challenge Test and Clinical Risk Factors. *Journal of clinical medicine* 2018;7(10) doi: 10.3390/jcm7100351[published Online First: Epub Date]].
32. Farrar D, Duley L, Dowswell T, Lawlor DA. Different strategies for diagnosing gestational diabetes to improve maternal and infant health. *The Cochrane database of systematic reviews* 2017;8:CD007122 doi: 10.1002/14651858.CD007122.pub4[published Online First: Epub Date]].
 33. Benhalima K, Minschart C, Ceulemans D, et al. Screening and Management of Gestational Diabetes Mellitus after Bariatric Surgery. *Nutrients* 2018;10(10) doi: 10.3390/nu10101479[published Online First: Epub Date]].
 34. Feichtinger M, Stopp T, Hofmann S, et al. Altered glucose profiles and risk for hypoglycaemia during oral glucose tolerance testing in pregnancies after gastric bypass surgery. *Diabetologia* 2017;60(1):153-57 doi: 10.1007/s00125-016-4128-8[published Online First: Epub Date]].
 35. Balsells M, Garcia-Patterson A, Sola I, Roque M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. *Bmj* 2015;350:h102 doi: 10.1136/bmj.h102[published Online First: Epub Date]].
 36. Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. *BMJ open diabetes research & care* 2018;6(1):e000456 doi: 10.1136/bmjdr-2017-000456[published Online First: Epub Date]].
 37. van Weelden W, Wekker V, de Wit L, et al. Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs. *Diabetes therapy : research, treatment and education of diabetes and related disorders* 2018;9(5):1811-29 doi: 10.1007/s13300-018-0479-0[published Online First: Epub Date]].
 38. Aroda VR, Christophi CA, Edelstein SL, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. *The Journal of clinical endocrinology and metabolism* 2015;100(4):1646-53 doi: 10.1210/jc.2014-3761[published Online First: Epub Date]].
 39. Benhalima K, Verstraete S, Muylle F, et al. Implementing a Reminder System in the Northern Part of Belgium to Stimulate Postpartum Screening for Glucose Intolerance in Women with Gestational Diabetes: The "Sweet Pregnancy" Project. *International journal of endocrinology* 2017;2017:3971914 doi: 10.1155/2017/3971914[published Online First: Epub Date]].
 40. Benhalima K, Van Crombrugge P, Moyson C, et al. Prediction of Glucose Intolerance in Early Postpartum in Women with Gestational Diabetes Mellitus Based on the 2013 WHO Criteria. *Journal of clinical medicine* 2019;8(3) doi: 10.3390/jcm8030383[published Online First: Epub Date]].
 41. Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. *The Cochrane database of systematic reviews* 2018;10:CD012661 doi: 10.1002/14651858.CD012661.pub2[published Online First: Epub Date]].
 42. Kim C, Herman WH, Vijan S. Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestational diabetes mellitus. *Diabetes care* 2007;30(5):1102-6 doi: 10.2337/dc06-2237[published Online First: Epub Date]].
 43. Buchanan TA, Page KA. Approach to the patient with gestational diabetes after delivery. *The Journal of clinical endocrinology and metabolism* 2011;96(12):3592-8 doi: 10.1210/jc.2011-1515[published Online First: Epub Date]].
 44. Gunderson EP, Lewis CE, Lin Y, et al. Lactation Duration and Progression to Diabetes in Women Across the Childbearing Years: The 30-Year CARDIA Study. *JAMA internal medicine*

509 **2018;178(3):328-37 doi: 10.1001/jamainternmed.2017.7978[published Online First: Epub**
510 **Date] |.**

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536 **Funding**

537 No funding was obtained for the development of the consensus.

538

539

540 **Disclosure statement**

541 The authors declare no conflict of interest.

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

Table 1: The 2009 institute of Medicine targets for gestational weight gain

	BMI (Kg/m ²)	Desired weight Gain (Kg)
Underweight	<18.5	12.5-18
Normal weight	18.5-24.9	11.5-16
Overweight	25-29.9	7-11.5
Obese	≥30	5-9

BMI: body mass index

Figure 1: The 2019 consensus on screening for overt diabetes and gestational diabetes mellitus

At pregnancy wish or at first prenatal visit: universal screening with fasting plasma glucose (FPG)

GDM: gestational diabetes mellitus; FPG: fasting plasma glucose; GCT: glucose challenge test; OGTT: oral glucose tolerance test; BMI: body mass index (kg/m^2); * no risk factors: if BMI < 30 and/or no previous history of GDM

Figure 2: Modified two-step screening for gestational diabetes applied to the BEDIP-N study

BEDIP-N: Belgian Diabetes in Pregnancy-North study; OGTT: oral glucose tolerance test; GCT: 50g glucose challenge test; GDM: gestational diabetes mellitus; NGT: normal glucose tolerance test

*clinical risk factor: BMI $\geq 30\text{Kg/m}^2$ or a previous history of GDM

Figure 3: Postpartum follow-up

- Universal screening with 2-h 75g OGTT 6-12 weeks postpartum (ADA criteria)
- Registration in 'Zoet Zwanger' project with yearly measurement of fasting plasma glucose by general physician

	Normal	Impaired glucose regulation	diabetes
Fasting	<100mg/dl	≥100 and <126mg/dl	≥ 126mg/dl
2-hour glucose on OGTT	<140mg/dl	≥140 en <200mg/dl	≥200mg/dl

OGTT: oral glucose tolerance test; ADA: American Diabetes Association